Therapeutics Articles
A systematic search of leading databases and registries by Chinese collaborators compared the efficacy of IVIG to routine care for hospitalized COVID-19 patients.
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
Findings in a recent study suggest that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus.
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.
Infusion of CSL112, an investigational human plasma-derived apolipoprotein A-1 formulated with phosphatidylcholine, rapidly and strongly elevates impaired cholesterol efflux capacity following acute myocardial infarction.
Investigators have found that intravenous immune globulin may have a positive effect on acute exacerbation of fibrotic idiopathic interstitial pneumonias.
Sanofi's fitusiran significantly reduced bleeding in a Phase III multinational study in adults and adolescents with hemophilia A or B, with or without inhibitors.
Italian investigators conducted a trial to assess the safety and efficacy of IVIG in treatment-resistant painful diabetic polyneuropathy (DPN).
Specialists at India’s Sir Ganga Ram Hospital conducted a double-blinded, randomized controlled study to examine the impact of high oncotic pressure priming by the addition of 20 percent human albumin prior to the initiation of CPB
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.
